Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 34

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 34
---
 ours make these potential issues significant.                                                                                      |

In addition to patents,
we also rely on trade secrets and proprietary know-how. We try to protect this information with appropriate confidentiality and inventions
agreements with our employees, scientific advisors, consultants, and collaborators. We cannot be sure that these agreements will not
be breached, that we will be able to protect ourselves if they are breached, or that our trade secrets will not otherwise become known
or be independently discovered by competitors. If any of these events occur, then we face the potential of losing control over valuable
company information, which could negatively affect our competitive position.

We may be unable to secure new patent protection for our LPLT-based immunization platform approach through additional patent applications, or may receive only partial claim approvals, which could limit the scope of intellectual property protection.

The one U.S. patent referenced relating to
the proprietary lipid-based delivery system developed in Prof. Barenholz’s laboratory at the Hebrew University of Jerusalem is
scheduled to expire on February 2027. This patent protects the composition and method of use of a liposomal nanoparticle platform incorporating
ceramide carbamoyl spermine (CCS) for the delivery of recombinant protein antigens in vaccine formulations. It includes composition of
matter claims and methods of use for prophylactic and therapeutic immunization.

This delivery system we are developing is
designed to optimize antigen presentation, enhance mucosal and systemic immunogenicity, and improve stability of co-encapsulated recombinant
proteins, as exemplified in preclinical studies involving SARS-CoV-2 and West Nile Virus (WNV) antigens. These studies showed promising
immunogenicity and protection outcomes in rodent models, however this needs to be further verified by future clinical trials.

<div align='center'>17</div>

As the Company advances its understanding of
the platform’s performance, it is preparing to file new patent applications covering the co-encapsulation of specific protein combinations
targeting additional viruses, including SARS-CoV-2 and West Nile Virus (WNV). The new patent applications will focus on the antigen-specific
compositions and immunization methods that are not covered by the original CCS delivery platform patents. These applications are expected
to be submitted following completion and internal review of the final reports from both the West Nile Virus and SARS-CoV-2 preclinical
proof-of-concept and challenge studies. These studies are designed to validate the underlying platform and antigen design